“We are proud to present data across our rapidly expanding hematology portfolio that validates our leading immuno-oncology approach and leverages our deep scientific expertise with the goal of improving outcomes for patients with hematologic malignancies,” Michael Giordano, senior vice president and head of development for oncology at Bristol-Myers Squibb, said. “Furthermore, we are committed to evaluating a broad range of rational combinations that have the potential to change long-term expectations for patients living with hematologic malignancies.”
The meeting will take place in Orlando, Florida, Dec. 5 through 7. Bristol-Myers Squibb representatives will discuss the company's clinical research related to medications it offers for hematology, including elotuzumab, which is used in the treatment of relapsed or refractory (R/R) multiple myeloma (MM); Opdivo (nivolumab), which is indicated for treatment of R/R classical Hodgkin lymphoma (cHL); and Sprycel (dasatinib), which is used in the treatment regimens of patients with chronic myeloid leukemia (CML).
The representatives will highlight survival data, comparative studies and case studies, as well as patient outcomes and possible adverse effects and drug interactions.
Bristol-Myers Squibb is a global BioPharma company.